Vaccines and multiple sclerosis: a systematic review

Mailand, Mia Topsøe; Frederiksen, Jette Lautrup

doi:10.1007/s00415-016-8263-4

Cited by 154Multiple Sclerosis Research StudiesImmune responses and vaccinationsPeripheral Neuropathies and Disorders

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Vaccines and multiple sclerosis: a systematic review

Mailand, Mia Topsøe, Frederiksen, Jette Lautrup·2017·Journal of Neurology

DOI 10.1007/s00415-016-8263-4

Open this paper in CoChat — free account

Abstract

Vaccinations are often the most effective tool against some disease known to mankind. This study offers a literature review on the role of vaccines regarding the risk of developing multiple sclerosis (MS) and MS relapse. The method used in this study is a systematic literature review on the database PubMed. The study found no change in risk of developing multiple sclerosis (MS) after vaccination against hepatitis B virus, human papillomavirus, seasonal influenza, measles-mumps-rubella, variola, tetanus, Bacillus Calmette-Guérin (BCG), polio, or diphtheria. No change in risk of relapse was found for influenza. Further research is needed for the potential therapeutic use of the BCG vaccine in patients in risk of developing MS and for the preventive potential of the tetanus and diphtheria vaccine.

Integrity signals

Registry

Crossref · 10.1007/s00415-016-8263-4

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Two recent systematic reviews concluded there was no relationship between receipt of a vaccine and development of multiple sclerosis.
“Two recent systematic reviews looking at the association between different individual vaccines and central demyelinating disorders (hepatitis B, human papilloma virus (HPV), influenza, MMR, varicella, tetanus, Bacillus Calmette Guérin (BCG), polio or diphtheria) concluded that there was no relationship between receipt of a vaccine and development of MS (Mailand and Frederiksen, 2017; Mouchet et al”
From Vaccine Safety: Myths and Misinformation (2020) · cites this paper as Mailand and Frederiksen, 2017
Existing epidemiologic studies have found no associations between the number of different vaccines and an increased risk of autoimmune disorders.
“Existing epidemiologic studies have found no associations between the number of different vaccines and an increased risk of autoimmune disorders.”
From Vaccine Safety: Myths and Misinformation (2020) · cites this paper as Mailand and Frederiksen, 2017

Vaccinations and the Risk of Relapse in Multiple Sclerosis
Confavreux, C., Suissa, S., Saddier, P., Bourdès, V., & Vukusic, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440501 · Cited by 490
Hepatitis B Vaccination and the Risk of Multiple Sclerosis
Ascherio, A., Zhang, S. M., Hernán, M. Á., Olek, M. J., COPLAN, P. M., Brodovicz, K. G., & Walker, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440502 · Cited by 433
Recombinant hepatitis B vaccine and the risk of multiple sclerosis
Hernán, M. Á., Jick, S. S., Olek, M. J., & Jick, H. (2004) · Neurology · doi:10.1212/01.wnl.0000138433.61870.82 · Cited by 302
Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults
Destefano, F. R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.4.504 · Cited by 256
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
Chao, C., Klein, N. P., Velicer, C. M., Sy, L. S., Slezak, J. M., Takhar, H. S., Ackerson, B. K., Cheetham, T. C., Hansen, J. R., Deosaransingh, K. A., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02467.x · Cited by 204
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases
Langer-Gould, A. M., Qian, L., Tartof, S. Y., Brara, S. M., Jacobsen, S. J., Beaber, B., Sy, L. S., Chao, C., Hechter, R. C., & Tseng, H. F. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2633 · Cited by 190
Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden
Bardage, C., Persson, I., Örtqvist, Å., Bergman, U., Ludvigsson, J. F., & Granath, F. (2011) · BMJ · doi:10.1136/bmj.d5956 · Cited by 190
Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System
Scheller, N. M., Svanström, H., Pasternak, B., Arnheim‐Dahlström, L., Sundström, K., Fink, K., & Hviid, A. P. (2015) · JAMA · doi:10.1001/jama.2014.16946 · Cited by 182
Use of Bacille Calmette–Guerin (BCG) in multiple sclerosis
Ristori, G., Buzzi, M. G., Sabatini, U., Giugni, E., Bastianello, S., Viselli, F., Buttinelli, C., Ruggieri, S. A., Colonnese, C., Pozzilli, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.7.1588 · Cited by 158
No increase in demyelinating diseases after hepatitis B vaccination
Zipp, F., Weil, J., & Einhäupl, K. M. (1999) · Nature Medicine · doi:10.1038/12376 · Cited by 156
Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS
Ristori, G., Romano, S., Cannoni, S., Visconti, A., Tinelli, E., Mendozzi, L., Cecconi, P., Lanzillo, R., Quarantelli, M., Buttinelli, C., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000438216.93319.ab · Cited by 153
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood
Mikaeloff, Y., Caridade, G., Suissa, S., & Tardieu, M. (2008) · Neurology · doi:10.1212/01.wnl.0000335762.42177.07 · Cited by 148
A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis
Miller, A., Morgante, L., Buchwald, L., Nutile, S., Coyle, P. K., Krupp, L., Doscher, C., LUBLIN, F. D., Knobler, R. L., Trantas, F., et al. (1997) · Neurology · doi:10.1212/wnl.48.2.312 · Cited by 147
School-based hepatitis B vaccination programme and adolescent multiple sclerosis
Sadovnick, A. D., & Scheifele, D. W. (2000) · The Lancet · doi:10.1016/s0140-6736(99)02991-8 · Cited by 139
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects
Grimaldi‐Bensouda, L., Guillemot, D., Godeau, B., Bénichou, J., Lebrun‐Frénay, C., Papeix, C., Labauge, P. M., Berquin, P. C., Penfornis, A., Benhamou, P., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12155 · Cited by 137
Risk factors of multiple sclerosis: a case-control study
Zorzon, M., Zivadinov, R., Nasuelli, D., Dolfini, P., Bosco, A., Bratina, A., Tommasi, M. A., Locatelli, L., & Cazzato, G. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0147-6 · Cited by 133
A case-control study of serious autoimmune adverse events following hepatitis B immunization
Geier, D. A., & Geier, M. R. (2005) · Autoimmunity · doi:10.1080/08916930500144484 · Cited by 132
Immunizations and risk of multiple sclerosis: systematic review and meta-analysis
Farez, M., & Correale, J. D. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5984-2 · Cited by 132
Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis
Keyser, J. D., Zwanikken, C., & Boon, M. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00139-7 · Cited by 114
Hepatitis B Vaccination and First Central Nervous System Demyelinating Event: A Case-Control Study
Touzé, E., Fourrier, A., Rue-Fenouche, C., Rondé-Oustau, V., Jeantaud, I., Bégaud, B., & Alpérovitch, A. (2002) · Neuroepidemiology · doi:10.1159/000059520 · Cited by 107
Vaccination against infection in patients with multiple sclerosis
Loebermann, M., Winkelmann, A., Hartung, H., Hengel, H., Reisinger, E. C., & Zettl, U. K. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.8 · Cited by 102
Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis
Farez, M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.131 · Cited by 101
VIRAL INFECTION IN PATIENTS WITH MULTIPLE SCLEROSIS AND HLA-DR MATCHED CONTROLS
Compston, D. A. S., Vakarelis, B. N., Paul, E. A., McDonald, W. I., Batchelor, J. R., & Mims, C. A. (1986) · Brain · doi:10.1093/brain/109.2.325 · Cited by 97
Association of Infectious Mononucleosis with Multiple Sclerosis
Ramagopalan, S. V., Valdar, W. S. J., Dyment, D. A., DeLuca, G. C., Yee, I. M. L., Giovannoni, G., Ebers, G. C., & Sadovnick, A. D. (2009) · Neuroepidemiology · doi:10.1159/000201564 · Cited by 96
Hepatitis B Vaccination and the Risk of Childhood-Onset Multiple Sclerosis
Mikaeloff, Y. (2007) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.161.12.1176 · Cited by 96
INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS*
Sibley, W. A., & Foley, J. M. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20229.x · Cited by 85
Environmental Risk Factors and Multiple Sclerosis: A Community-Based, Case-Control Study in the Province of Ferrara, Italy
Casetta, I., Granieri, E., Malagù, S., Tola, M. R., Paolino, E., Caniatti, L. M., Govoni, V., Monetti, V. C., & Fainardi, E. (1994) · Neuroepidemiology · doi:10.1159/000110369 · Cited by 84
Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination
Mikaeloff, Y., Caridade, G., Assi, S., Tardieu, M., Suissa, S., & on behalf of the KIDSEP study group of the French Neuropaediatric Society (2006) · Brain · doi:10.1093/brain/awl368 · Cited by 83
Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France
Berr, C., Puel, J., Clanet, M., Ruidavets, J., Mas, J., & Alpérovitch, A. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb03841.x · Cited by 83
Infection Risk in Patients on Multiple Sclerosis Therapeutics
Williamson, E. M. L., & Berger, J. R. (2015) · CNS Drugs · doi:10.1007/s40263-015-0226-2 · Cited by 60
Clinical evaluation of possible etiologic factors in multiple sclerosis
Alter, M., & Speer, J. (1968) · Neurology · doi:10.1212/wnl.18.2.109 · Cited by 60
Influenza vaccination in MS
Moriabadi, N. F., Niewiesk, S., Kruse, N., Jung, S., Weißbrich, B., ter Meulen, V., Toyka, K. V., & Rieckmann, P. (2001) · Neurology · doi:10.1212/wnl.56.7.938 · Cited by 57
Multiple sclerosis in the Faroe Islands
Kurtzke, J. F., Hyllested, K., Arbuckle, J. D., Brønnum‐Hansen, H., Wallin, M. T., Heltberg, A., Jacobsen, H., Olsen, A., & Eriksen, L. S. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00258.x · Cited by 54
Risk factors in multiple sclerosis: Tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy
Andersen, E., Isager, H., & Hyllested, K. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb00756.x · Cited by 52
A population-based case–control study on viral infections and vaccinations and subsequent multiple sclerosis risk
Ahlgren, C., Torén, K., Odén, A., & Andersen, O. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9367-2 · Cited by 47
Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations
Ahlgren, C., Odén, A., Torén, K., & Andersen, O. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01131.x · Cited by 45
Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case–control study using the self-controlled case series method
Hocine, M. N., Farrington, P., Touzé, E., Whitaker, H., Fourrier, A., Moreau, T., & Tubert‐Bitter, P. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.05.032 · Cited by 42
Multiple sclerosis in India: a case-control study of environmental exposures
Bansil, S., Singhal, B. S., Gk, A., Riise, T., Ladiwala, U., Behari, M., & Cook, S. D. (1997) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00075.x · Cited by 41
Vaccinations and multiple sclerosis
Gout, O. (2001) · Neurological Sciences · doi:10.1007/s100720170014 · Cited by 39
Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination
Salvetti, M., Pisani, A., Bastianello, S., Millefiorini, E., Buttinelli, C., & Pozzilli, C. (1995) · Journal of Neurology · doi:10.1007/bf00936886 · Cited by 39
Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B
Merelli, E., & Casoni, F. (2000) · Neurological Sciences · doi:10.1007/s100720070025 · Cited by 38
A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis
Baumhackl, U., Franta, C., Retzl, J., Salomonowitz, E. K., & Eder, G. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00815-0 · Cited by 37
Hepatitis B vaccine and risk of multiple sclerosis
Destefano, F. R., Verstraeten, T., & Chen, R. T. (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.4.461 · Cited by 37
Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review
Demicheli, V., Rivetti, A., Pietrantonj, C. D., Clements, C. J., & Jefferson, T. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00423.x · Cited by 36
Risk factors for multiple sclerosis: a case-control study in Israel
Zilber, N., & Kahana, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb00051.x · Cited by 35
Swine Influenza Vaccination in Patients With Multiple Sclerosis
Bamford, C. R., Sibley, W. A., & Laguna, J. F. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500280060012 · Cited by 34
Influenza Vaccination in Patients With Multiple Sclerosis
Sibley, W. A. (1976) · JAMA · doi:10.1001/jama.1976.03270180041018 · Cited by 34
Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination
McNicholas, N., & Chataway, J. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5944-x · Cited by 33
Swine Influenza Virus Vaccination in Patients with Multiple Sclerosis
Myers, L. W., Ellison, G. W., Lucia, M., NOVOM, S., Mi, H., Madden, D. L., Sever, J. L., & Noble, G. R. (1977) · The Journal of Infectious Diseases · doi:10.1093/infdis/136.supplement_3.s546 · Cited by 30
Influenza virus vaccination of patients with multiple sclerosis
Mokhtarian, F., Shirazian, D., Morgante, L., Miller, A., Grob, D., & Lichstein, E. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300405 · Cited by 29
Mass Vaccination Against Hepatitis B: The French Example
Denis, F., & Lévy-Bruhl, D. (2006) · Springer eBooks · doi:10.1007/3-540-36583-4_7 · Cited by 26
Multiple sclerosis and immunological-related risk factors: Results from a case-control study
Eftekharian, M. M., Mousavi, M., Hormoz, M. B., Roshanaei, G., & Mazdeh, M. (2015) · Human Antibodies · doi:10.3233/hab-150281 · Cited by 25
H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study
Farez, M., Ysrraelit, M. C., Fiol, M. P., & Correale, J. D. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511417253 · Cited by 25
Seasonal and H1N1v influenza vaccines in MS: Safety and compliance
Auriel, E., Gadoth, A., Regev, K., & Karni, A. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.10.013 · Cited by 24
Childhood Infections as Risk Factors for Multiple Sclerosis: Belgrade Case-Control Study
Pekmezovic, T. D., Jarebinski, M., & Drulovic, J. S. (2004) · Neuroepidemiology · doi:10.1159/000080094 · Cited by 22
Demyelinating Disease and Hepatitis B Vaccination
Jefferson, T., & Heijbel, H. (2001) · Drug Safety · doi:10.2165/00002018-200124040-00002 · Cited by 19
Serial Magnetic Resonance Imaging Studies with Paramagnetic Contrast Medium: Assessment of Disease Activity in Patients with Multiple Sclerosis before and after Influenza Vaccination
Michielsens, B., Wilms, G. E., Marchal, G., & Carton, H. (2008) · European Neurology · doi:10.1159/000117358 · Cited by 18
Vaccination of patients with Encephalomyelitis disseminata
Quast, U., Herder, C., & Zwisler, O. (1991) · Vaccine · doi:10.1016/0264-410x(91)90104-e · Cited by 18
No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus
Pellegrino, P., Carnovale, C., Perrone, V., Antoniazzi, S., Pozzi, M., Clementi, E., & Radice, S. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9830-y · Cited by 17
Methodological Issues With the Risk of Relapse Study in Patients With Multiple Sclerosis After Yellow Fever Vaccination
Pool, V. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1519 · Cited by 14
Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes
Özakbaş, S., İdıman, E., Yuluğ, B., Paköz, Z. B., Bahar, H., & Gülay, Z. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00653.x · Cited by 9
Relationship between Vaccinations and Multiple Sclerosis
Sievers, E. J., & Heyneman, C. A. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph10420 · Cited by 6
Relationship Between Vaccinations and Multiple Sclerosis
Sievers, E. J., & Heyneman, C. A. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a096 · Cited by 5

Flagged first, then by citations

Sorted by citations

Vaccine Safety: Myths and Misinformation
Geoghegan, S., O’Callaghan, K. P., & Offit, P. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00372 · Cited by 275
“A metanalysis of 39 controlled observational studies found that the relative risk of GBS following receipt of any influenza vaccine was 1.41 (Martin Arias et al., 2015).”
Influential
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
Achiron, A., Dolev, M., Menascu, S., Zohar, D. N., Dreyer-Alster, S., Miron, S., Shirbint, E., Magalashvili, D., Flechter, S., Givon, U., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211003476 · Cited by 212
Ocular Adverse Events After COVID-19 Vaccination
Ng, X. L., Betzler, B. K., Testi, I., Ho, S. L., Tien, M. C.-H., Ngo, W. K., Zierhut, M., Chee, S.-P., Gupta, V., Pavesio, C. E., et al. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1976221 · Cited by 183
Impfen bei Immundefizienz
Wagner, N., Assmus, F., Arendt, G., Baum, E., Baumann, U., Bogdan, C., Burchard, G. D., Föll, D., Garbe, E., Hecht, J., et al. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02905-1 · Cited by 150
Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Ciotti, J. R., Valtcheva, M. V., & Cross, A. H. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102439 · Cited by 135
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
Khayat-Khoei, M., Bhattacharyya, S., Katz, J., Harrison, D. S., Tauhid, S., Bruso, P., Houtchens, M. K., Edwards, K. R., & Bakshi, R. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10780-7 · Cited by 128
A systematic review of cases of CNS demyelination following COVID-19 vaccination
Ismail, I. I., & Salama, S. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577765 · Cited by 128
The potential neurological effect of the COVID‐19 vaccines: A review
Lu, L., Xiong, W., Mu, J., Zhang, Q., Zhang, H., Zou, L., Li, W., He, L., Sander, J. W. A. S., & Zhou, D. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13417 · Cited by 104
Impfen bei Immundefizienz
Niehues, T., Bogdan, C., Hecht, J., Mertens, T., Wiese‐Posselt, M., & Zepp, F. (2017) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-017-2555-4 · Cited by 97
Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
Olberg, H. K., Eide, G. E., Cox, R. J., Jul‐Larsen, Å., Lartey, S. L., Vedeler, C. A., & Myhr, K.-M. (2017) · European Journal of Neurology · doi:10.1111/ene.13537 · Cited by 92
Vaccination in Multiple Sclerosis: Friend or Foe?
Zrzavy, T., Kollaritsch, H., Rommer, P. S., Boxberger, N., Loebermann, M., Wimmer, I., Winkelmann, A., & Zettl, U. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01883 · Cited by 85
Administration of COVID-19 vaccines in immunocompromised patients
Negahdaripour, M., Shafiekhani, M., Moezzi, S. M. I., Amiri, S., Rasekh, S., Bagheri, A., Mosaddeghi, P., & Vazin, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108021 · Cited by 79
Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies
Metze, C., Winkelmann, A., Loebermann, M., Hecker, M., Schweiger, B., Reisinger, E. C., & Zettl, U. K. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13034 · Cited by 79
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Álvarez, E., Longbrake, E. E., Rammohan, K. W., Stankiewicz, J. M., & Hersh, C. M. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105009 · Cited by 81
Advancements in protein nanoparticle vaccine platforms to combat infectious disease
Butkovich, N., Li, E., Ramirez, A., Burkhardt, A. M., & Wang, S. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1681 · Cited by 73
Role of environmental factors in multiple sclerosis
Zarghami, A., Li, Y., Claflin, S. B., van der Mei, I. A. F., & Taylor, B. V. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1978843 · Cited by 64
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement
Riva, A., Barcella, V., Benatti, S. V., Capobianco, M. A. N., Capra, R., Cinque, P. M., Comi, G., Fasolo, M., Franzetti, F., Galli, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520952310 · Cited by 66
Protecting people with multiple sclerosis through vaccination
Reyes, S., Ramsay, M. E., Ladhani, S. N., Amirthalingam, G., Singh, N., Bartolomé, C. C., Mathews, J., Lambourne, J., Marta, M., Turner, B. P., et al. (2020) · Practical Neurology · doi:10.1136/practneurol-2020-002527 · Cited by 64
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
Toljan, K., Amin, M., Kunchok, A. C., & Ontaneda, D. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577785 · Cited by 61
Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel
Lotan, I., Wilf‐Yarkoni, A., Friedman, Y., Stiebel‐Kalish, H., Steiner, I., & Hellmann, M. A. (2021) · European Journal of Neurology · doi:10.1111/ene.15028 · Cited by 59
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 63
Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes?
Principi, N., & Esposito, S. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00361 · Cited by 54
Hepatitis B vaccination and the putative risk of central demyelinating diseases – a systematic review and meta-analysis.
Mouchet, J., Salvo, F., Raschi, E., Poluzzi, E., Antonazzo, I. C., De Ponti, F., & Bégaud, B. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.036 · Cited by 49
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
Nistri, R., Barbuti, E., Rinaldi, V., Tufano, L., Pozzilli, V., Ianniello, A., Marinelli, F., Luca, G. D., Prosperini, L., Tomassini, V., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.765954 · Cited by 50
Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis
Mouchet, J., Salvo, F., Raschi, E., Poluzzi, E., Antonazzo, I. C., Ponti, F. D., & Bégaud, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.007 · Cited by 47
Management of Multiple Sclerosis Relapses
Repovic, P. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000739 · Cited by 45
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases
Lotan, I., Romanow, G., & Levy, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103189 · Cited by 44
A large case-control study on vaccination as risk factor for multiple sclerosis
Hapfelmeier, A., Gasperi, C., Donnachie, E., & Hemmer, B. (2019) · Neurology · doi:10.1212/wnl.0000000000008012 · Cited by 44
Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder
Mealy, M. A., Cook, L. J., Pache, F. C., Velez, D. L., Borisow, N., Becker, D., Arango, J. A. J., Paul, F., & Levy, M. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.05.003 · Cited by 43
Voltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy
Cheng, S., Jiang, D., Lan, X., Liu, K., & Fan, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116651 · Cited by 42
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Schweitzer, F., Laurent, S. A., Fink, G. R., Barnett, M. H., Hartung, H., & Warnke, C. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09690-6 · Cited by 40
Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options
Wang, Y., Wang, J., & Feng, J. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103449 · Cited by 42
Case Report: Postvaccination Anti–Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder
Kumar, N., Graven, K., Joseph, N., Johnson, J., Fulton, S. A., Hostoffer, R., & Abboud, H. (2019) · International Journal of MS Care · doi:10.7224/1537-2073.2018-104 · Cited by 37
Hepatitis B Vaccine: Four Decades on
Mironova, M., & Ghany, M. G. (2024) · Vaccines · doi:10.3390/vaccines12040439 · Cited by 41
Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients
Sansone, G., & Bonifati, D. M. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11140-9 · Cited by 34
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis
Vitturi, B. K., Cellerino, M., Boccia, V. D., Leray, E., Correale, J. D., Dobson, R., van der Mei, I. A. F., Fujihara, K., & Inglese, M. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13248-0 · Cited by 32
Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway
Ghaderi, S., Berg‐Hansen, P., Bakken, I. J., Magnus, P. M., Trogstad, L., & Håberg, S. E. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-019-00595-2 · Cited by 31
Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines
Omersel, J., & Kuželički, N. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113561 · Cited by 33
A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats.
Fan, C., Long, R., You, Y., Wang, J., Yang, X.-F., Huang, S., Sheng, Y., Peng, X., Liu, H., Wang, Z.-H., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.012 · Cited by 29
Clinical practice guidelines 2019: Indian consensus-based recommendations on influenza vaccination in adults
Dhar, R., Ghoshal, A. G., Guleria, R., Sharma, S., Kulkarni, T., Swarnakar, R., Samaria, J., Chaudhary, S., Gaur, S., Christopher, D., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_270_20 · Cited by 29
Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
Wendel‐Haga, M., & Celius, E. G. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12844 · Cited by 28
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society
Nojszewska, M., Kalinowska, A., Adamczyk-Sowa, M. H., Kułakowska, A., & Bartosik-Psujek, H. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0016 · Cited by 28
Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection
Moscicki, A., Flowers, L., Huchko, M. J., Long, M. E., MacLaughlin, K. L., Murphy, J., Spiryda, L. B., Scheckel, C., & Gold, M. A. (2025) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000866 · Cited by 26
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment
Otero‐Romero, S., Sánchez‐Montalvá, A., & Vidal‐Jordana, Á. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1886924 · Cited by 28
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
Kantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 25
Negative perceptions of hepatitis B vaccination among attendees of an urban free testing center for sexually transmitted infections in France
Moyroud, L., Hustache, S., Goirand, L., Hauzanneau, M., & Épaulard, O. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1264549 · Cited by 21
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey
Huang, Y., Rodgers, J., Middleton, R., Baheerathan, A., Tuite-Dalton, K., Ford, D. V., & Nicholas, R. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103175 · Cited by 20
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis
Brill, L., Rechtman, A., Zveik, O., Haham, N., Levin, N., Shifrin, A., Rozenberg, A., & Vaknin‐Dembinsky, A. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103343 · Cited by 21
Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
Tsur, S. W., Zaher, E. A., Tsur, M., Kania, K., & Kalinowska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083859 · Cited by 21
Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
Ziello, A. R., Scavone, C., Battista, M. E. D., Salvatore, S., Cesare, D. D. G., Moreggia, O., Allegorico, L., Sagnelli, A., Barbato, S., Manzo, V., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070890 · Cited by 18
Vaccines and multiple sclerosis
Frederiksen, J. L., & Mailand, M. T. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12837 · Cited by 18
Self-citation
A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
Ballout, A. A., Babaie, A., Kolesnik, M., Li, J. Y., Hameed, N., Waldman, G., Chaudhry, F., Saba, S., Harel, A., & Najjar, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.796882 · Cited by 18
Vaccine hesitancy and illness perceptions: comparing parents of children with autism spectrum disorder to other parent groups
Sahni, L. C., Boom, J. A., Mire, S. S., Berry, L. N., Dowell, L. R., Minard, C. G., Cunningham, R. M., & Goin‐Kochel, R. P. (2020) · Children s Health Care · doi:10.1080/02739615.2020.1740883 · Cited by 18
COVID-19 vaccination in people with multiple sclerosis, real-life experience
Alroughani, R., Al-Hashel, J., Abokalawa, F., AlMojel, M., & Ahmed, S. F. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107374 · Cited by 16
Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups
Grimaldi‐Bensouda, L., Papeix, C., Hamon, Y., Buchard, A., Moride, Y., Bénichou, J., Duchemin, T., & Abenhaim, L. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2968 · Cited by 16
Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis
Abbadessa, G., Lavorgna, L., Trojsi, F., Coppola, C., & Bonavita, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1957673 · Cited by 15
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
Carvajal, R., Zabalza, A., Carbonell‐Mirabent, P., Martínez‐Gómez, X., Esperalba, J., Pappolla, A., Rando‐Segura, A., Cobo‐Calvo, Á., Tur, C., Rodríguez, M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6345 · Cited by 15
Zika Virus and Neurologic Disease
Reid, S., Rimmer, K., & Thakur, K. T. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.06.003 · Cited by 15
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Gold, R., Fätkenheuer, G., Hartung, H., Kleinschnitz, C., Marks, R., Maschke, M., Bayas, A., Löbermann, M., Zettl, U. K., & Wiendl, H. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211019598 · Cited by 15
A matched case-control study of risk factors associated with multiple sclerosis in Kuwait
El-Muzaini, H., Akhtar, S., & Alroughani, R. (2020) · BMC Neurology · doi:10.1186/s12883-020-01635-1 · Cited by 15
Coronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia?
Lima, M., Aloizou, A., Siokas, V., Bakirtzis, C., Liampas, I., Tsouris, Z., Bogdanos, D. P., Balogiannis, S., & Dardiotis, E. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0148 · Cited by 34
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
Etemadifar, M., Abhari, A. P., Nouri, H., Akhavan-Sigari, A., Daliyeh, S. M. P., Maracy, M. R., Salari, M., Maleki, S., & Sedaghat, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2041945 · Cited by 14
Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model
Choi, T. S. T., Chan, B. A., Grech, L., Kwok, A., Webber, K., Wong, J., Nguyen, M., Bain, N. T., Day, D., McCartney, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020239 · Cited by 13
Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023
Meca-Lallana, J. E., Martínez‐Yélamos, S., Eichau, S., Llaneza, M. Á., Martínez, J. M., Martínez, J. P., Lallana, V. M., Alonso, A., Torres, E. M., Río, J., et al. (2024) · Neurología · doi:10.1016/j.nrl.2023.06.001 · Cited by 13
Infections of the Central Nervous System in Returning Travelers and Immigrants
Thompson, H., & Thakur, K. T. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0594-5 · Cited by 13
Vaccination in multiple sclerosis ‑ Challenging practices (Review)
Sîrbu, C. A., Florea, A., Ghinescu, M. C., Axelerad, A. D., Sirbu, A. M., Bratu, O. G., & Radu, F. I. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9347 · Cited by 13
Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity
Kavosh, A., Ashtari, F., Naghavi, S., Adibi, I., Shaygannejad, V., Karimi, Z., Arabi, S., Rahimi, M., & Mazaheri, S. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103708 · Cited by 12
Vaccine-associated measles in a patient treated with natalizumab: a case report
Miauton, A., Tan, R., Pantazou, V., Pasquier, R. D., & Genton, B. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05475-9 · Cited by 12
Multiple Sclerosis Relapse Following COVID-19 Vaccination: A Case Report and Literature Review
Kataria, S., Rogers, S., Bilal, U., Baktashi, H., & Singh, R. (2022) · Cureus · doi:10.7759/cureus.21374 · Cited by 11
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Pugliatti, M., Hartung, H., Oreja‐Guevara, C., Pozzilli, C., Airas, L. M., Alkhawajah, M. M., Grigoriadis, N., Magyari, M., Wijmeersch, B. V., Zakaria, M. F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1045101 · Cited by 11
New Onset Multiple Sclerosis Post-COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study
Alluqmani, M. M. (2023) · Cureus · doi:10.7759/cureus.36323 · Cited by 10
Neurologic Complications With Vaccines
Nath, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207337 · Cited by 10
Perspectives and experiences with COVID-19 vaccines in people with MS
Ciotti, J. R., Perantie, D. C., Moss, B. P., Fitzgerald, K. C., Cohen, J. A., Mowry, E. M., Naismith, R. T., & Chahin, S. (2022) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173221085242 · Cited by 10
Can Vaccination Trigger Autoimmune Disorders? A Meta-Analysis
Petráš, M., Lesná, I. K., Dáňová, J., & Čelko, A. M. (2021) · Vaccines · doi:10.3390/vaccines9080821 · Cited by 10
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database
Kim, J., Park, J., & Song, T. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221109397 · Cited by 10
Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis
Houen, G., Heiden, J., Trier, N. H., Draborg, A. H., Benros, M. E., Zinkevičiūtė, R., Petraitytė-Burneikienė, R., Čiplys, E., Slibinskas, R., & Frederiksen, J. L. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577314 · Cited by 10
Self-citation
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies
Scavone, C., Cagnotta, C., Sportiello, L., Maniscalco, G. T., Ragone, A., Frasca, M., Rinaldi, B., & Capuano, A. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2574668 · Cited by 9
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Meca-Lallana, J. E., Martínez‐Yélamos, S., Eichau, S., Llaneza, M. Á., Martínez, J. M., Martínez, J. P., Lallana, V. M., Alonso, A., Torres, E. M., Río, J., et al. (2024) · Neurología (English Edition) · doi:10.1016/j.nrleng.2024.01.003 · Cited by 9
CONTENT REVIEW OF VACCINES AND VACCINATION RELATED NEWS IN INTERNET NEWSPAPERS
TEKER, A. G. (2019) · Eskişehir Türk Dünyası Uygulama ve Araştırma Merkezi Halk Sağlığı Dergisi · doi:10.35232/estudamhsd.498789 · Cited by 9
Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?
Shi, Y., Guo, M., Yang, W., Liu, S., Zhu, B., Yang, L., Yang, C., & Liu, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1911653 · Cited by 9
Vaccinations in patients with multiple sclerosis: review and recommendations
Nesbitt, C., Rath, L., Zhong, M., Cheng, A. C., Butzkueven, H., Wesselingh, R., Skibina, O. G., Monif, M., Yeh, W. Z., Brotherton, J. M. L., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51012 · Cited by 8
COVID-19 Vaccine Status, Intent, Hesitancy, and Disease-Related Beliefs in People with Multiple Sclerosis
Grech, L., Kwok, A., Nguyen, M., Winkel, A., Butler, E. G., Allan, M., Bain, N. T., Segelov, E., & on behalf of the MSVACCS Investigators (2023) · Vaccines · doi:10.3390/vaccines11020410 · Cited by 8
Demonstration of background rates of three conditions of interest for vaccine safety surveillance
Wormsbecker, A. E., Johnson, C., Bourns, L., Harris, T. M., Crowcroft, N. S., & Deeks, S. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210833 · Cited by 8
General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis
Streckenbach, B., Baldt, J., Heidler, F., Frahm, N., Langhorst, S. E., Mashhadiakbar, P., Burian, K., Zettl, U. K., & Richter, J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.012 · Cited by 8
Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis
Langhorst, S. E., Frahm, N., Hecker, M., Mashhadiakbar, P., Streckenbach, B., Baldt, J., Heidler, F., & Zettl, U. K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050677 · Cited by 8
Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study
Heidler, F., Baldt, J., Frahm, N., Langhorst, S. E., Mashhadiakbar, P., Streckenbach, B., Zettl, U. K., & Richter, J. (2021) · European Neurology · doi:10.1159/000519582 · Cited by 8
The Role and Safety of Aluminum Adjuvants in Childhood Vaccines
Nirenberg, E., Maldonado, Y., & Hoffman, S. A. (2025) · PEDIATRICS · doi:10.1542/peds.2025-074874 · Cited by 7
Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity
Kim, E., Haag, A., Nguyen, J., Kesselman, M. M., & Beckler, M. D. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104172 · Cited by 7
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination
Labani, A., Chou, S., Kaviani, K., Ropero, B., Russman, K. M., & Becker, D. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104865 · Cited by 7
Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?
Gernert, J. A., Zimmermann, H., Oswald, E., Christmann, T., Kümpfel, T., & Havla, J. B. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104175 · Cited by 7
Association between vaccination and the risk of central demyelination: results from a case-referent study
Grimaldi‐Bensouda, L., Papeix, C., Hamon, Y., Bénichou, J., & Abenhaim, L. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11822-y · Cited by 13
Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis
Marantos, T., Kyriazopoulou, E., Lekakis, V., Voumvourakis, K. I., & Tsiodras, S. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122852 · Cited by 7
Vaccines and disease-modifying treatments
Waubant, E. L., Giovannoni, G., Hawkes, C. H., & Levy, M. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.10.017 · Cited by 7
Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study
Marantos, T., Kyriazopoulou, E., Angelakis, E., Kitsos, D. K., Chondrogianni, M. E., Mpizta, G., Papadopoulos, A., Giannopoulos, S., Voumvourakis, K. I., & Tsiodras, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.049 · Cited by 6
There Is No Evidence That Inactivated COVID-19 Vaccines Increase Risks of Uveitis Flare
Song, H., Zhao, C., & Zhang, M. (2022) · Vaccines · doi:10.3390/vaccines10101680 · Cited by 6
Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination
Georganta, I., Chasapi, D., Smith, C. J., Kopsidas, K., & Tatham, A. J. (2023) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2023-001336 · Cited by 6
Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report
Ahadi, M. S., Ghadiri, F., ahraian, M. A., & Moghadasi, A. N. (2021) · Acta Neurologica Belgica · doi:10.1007/s13760-021-01775-2 · Cited by 6
Shared breastfeeding & other early multiple sclerosis risk factors: A case-control study
Alkhawajah, N. M., Hussain‐Alkhateeb, L., Alshamlan, Y. A., Almohaini, M. O., Aleissa, G. A., Muayqil, T. A., & Aljarallah, S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102812 · Cited by 5
Relationship between medical history and multiple sclerosis: A-case-control study
Esfandiari, F., Ghazaiean, M., Darvishi‐Khezri, H., & Baghbanian, S. M. (2023) · Medicine · doi:10.1097/md.0000000000033906 · Cited by 5
Vaccination and Autoimmune Phenomena
Janković, S. (2017) · The Central European Journal of Paediatrics · doi:10.5457/p2005-114.165 · Cited by 5

Authors: Mailand, M. T., & Frederiksen, J. L.
Affiliations: University of Copenhagen (DK)
Corresponding author: Frederiksen, Jette Lautrup
ORCID: Mailand, Mia Topsøe
Frederiksen, Jette Lautrup
Venue: Journal of Neurology
Publisher: Springer Science and Business Media LLC
Published: 2016-09-07
Volume: 264
Issue: 6
Pages: 1035-1050
ISSN: 0012-1037 (ISSN-L)
0340-5354
1432-1459
DOI: 10.1007/s00415-016-8263-4
OpenAlex: W2514636267
Cited by: 154
References: 63
Citations by year: 2026: 3 · 2025: 7 · 2024: 14 · 2023: 23 · 2022: 20 · 2021: 32 · 2020: 22 · 2019: 12 · 2018: 14 · 2017: 6 · 2016: 1
FWCI: 1.73
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Journal of Neurology (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Keywords: multiple sclerosis, vaccines, hepatitis B vaccine, HPV vaccine, seasonal influenza vaccine, MMR vaccine, smallpox vaccine, tetanus vaccine, BCG vaccine, diphtheria vaccine, polio vaccine, multiple sclerosis risk, relapse
MeSH terms: Animals, Humans, Multiple Sclerosis, Vaccination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccines and multiple sclerosis: a systematic review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks